Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations
Background: The development of cancer and anti-tumor therapies can lead to systemic immune alterations but little is known about how long immune dysfunction persists in cancer survivors. Methods: We followed changes in the cellular immune parameters of prostate cancer patients with good prognostic c...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/13/3058 |
| _version_ | 1797480722708037632 |
|---|---|
| author | Katalin Balázs Zsuzsa S. Kocsis Péter Ágoston Kliton Jorgo László Gesztesi Gyöngyi Farkas Gábor Székely Zoltán Takácsi-Nagy Csaba Polgár Géza Sáfrány Zsolt Jurányi Katalin Lumniczky |
| author_facet | Katalin Balázs Zsuzsa S. Kocsis Péter Ágoston Kliton Jorgo László Gesztesi Gyöngyi Farkas Gábor Székely Zoltán Takácsi-Nagy Csaba Polgár Géza Sáfrány Zsolt Jurányi Katalin Lumniczky |
| author_sort | Katalin Balázs |
| collection | DOAJ |
| description | Background: The development of cancer and anti-tumor therapies can lead to systemic immune alterations but little is known about how long immune dysfunction persists in cancer survivors. Methods: We followed changes in the cellular immune parameters of prostate cancer patients with good prognostic criteria treated with low dose rate brachytherapy before and up to 3 years after the initiation of therapy. Results: Patients before therapy had a reduced CD4+ T cell pool and increased regulatory T cell fraction and these alterations persisted or got amplified during the 36-month follow-up. A significant decrease in the total NK cell number and a redistribution of the circulating NK cells in favor of a less functional anergic subpopulation was seen in patients before therapy but tumor regression led to the regeneration of the NK cell pool and functional integrity. The fraction of lymphoid DCs was increased in patients both before therapy and throughout the whole follow-up. Increased PDGF-AA, BB, CCL5 and CXCL5 levels were measured in patients before treatment but protein levels rapidly normalized. Conclusions: while NK cell dysfunction recovered, long-term, residual alterations persisted in the adaptive and partly in the innate immune system. |
| first_indexed | 2024-03-09T22:04:11Z |
| format | Article |
| id | doaj.art-17515a3dd8724d928dc71b057ba95117 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T22:04:11Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-17515a3dd8724d928dc71b057ba951172023-11-23T19:43:42ZengMDPI AGCancers2072-66942022-06-011413305810.3390/cancers14133058Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune AlterationsKatalin Balázs0Zsuzsa S. Kocsis1Péter Ágoston2Kliton Jorgo3László Gesztesi4Gyöngyi Farkas5Gábor Székely6Zoltán Takácsi-Nagy7Csaba Polgár8Géza Sáfrány9Zsolt Jurányi10Katalin Lumniczky11National Public Health Center, Unit of Radiation Medicine, Department of Radiobiology and Radiohygiene, 1221 Budapest, HungaryDepartment of Radiobiology and Diagnostic Onco-Cytogenetics and The National Tumorbiology Laboratory, Centre of Radiotherapy, National Institute of Oncology, 1122 Budapest, HungaryCentre of Radiotherapy and The National Tumorbiology Laboratory, National Institute of Oncology, 1122 Budapest, HungaryCentre of Radiotherapy and The National Tumorbiology Laboratory, National Institute of Oncology, 1122 Budapest, HungaryCentre of Radiotherapy and The National Tumorbiology Laboratory, National Institute of Oncology, 1122 Budapest, HungaryDepartment of Radiobiology and Diagnostic Onco-Cytogenetics and The National Tumorbiology Laboratory, Centre of Radiotherapy, National Institute of Oncology, 1122 Budapest, HungaryDepartment of Radiobiology and Diagnostic Onco-Cytogenetics and The National Tumorbiology Laboratory, Centre of Radiotherapy, National Institute of Oncology, 1122 Budapest, HungaryCentre of Radiotherapy and The National Tumorbiology Laboratory, National Institute of Oncology, 1122 Budapest, HungaryCentre of Radiotherapy and The National Tumorbiology Laboratory, National Institute of Oncology, 1122 Budapest, HungaryNational Public Health Center, Unit of Radiation Medicine, Department of Radiobiology and Radiohygiene, 1221 Budapest, HungaryDepartment of Radiobiology and Diagnostic Onco-Cytogenetics and The National Tumorbiology Laboratory, Centre of Radiotherapy, National Institute of Oncology, 1122 Budapest, HungaryNational Public Health Center, Unit of Radiation Medicine, Department of Radiobiology and Radiohygiene, 1221 Budapest, HungaryBackground: The development of cancer and anti-tumor therapies can lead to systemic immune alterations but little is known about how long immune dysfunction persists in cancer survivors. Methods: We followed changes in the cellular immune parameters of prostate cancer patients with good prognostic criteria treated with low dose rate brachytherapy before and up to 3 years after the initiation of therapy. Results: Patients before therapy had a reduced CD4+ T cell pool and increased regulatory T cell fraction and these alterations persisted or got amplified during the 36-month follow-up. A significant decrease in the total NK cell number and a redistribution of the circulating NK cells in favor of a less functional anergic subpopulation was seen in patients before therapy but tumor regression led to the regeneration of the NK cell pool and functional integrity. The fraction of lymphoid DCs was increased in patients both before therapy and throughout the whole follow-up. Increased PDGF-AA, BB, CCL5 and CXCL5 levels were measured in patients before treatment but protein levels rapidly normalized. Conclusions: while NK cell dysfunction recovered, long-term, residual alterations persisted in the adaptive and partly in the innate immune system.https://www.mdpi.com/2072-6694/14/13/3058prostate cancerradiotherapyimmune phenotypingadaptive immune responseinnate immune response |
| spellingShingle | Katalin Balázs Zsuzsa S. Kocsis Péter Ágoston Kliton Jorgo László Gesztesi Gyöngyi Farkas Gábor Székely Zoltán Takácsi-Nagy Csaba Polgár Géza Sáfrány Zsolt Jurányi Katalin Lumniczky Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations Cancers prostate cancer radiotherapy immune phenotyping adaptive immune response innate immune response |
| title | Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations |
| title_full | Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations |
| title_fullStr | Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations |
| title_full_unstemmed | Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations |
| title_short | Prostate Cancer Survivors Present Long-Term, Residual Systemic Immune Alterations |
| title_sort | prostate cancer survivors present long term residual systemic immune alterations |
| topic | prostate cancer radiotherapy immune phenotyping adaptive immune response innate immune response |
| url | https://www.mdpi.com/2072-6694/14/13/3058 |
| work_keys_str_mv | AT katalinbalazs prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT zsuzsaskocsis prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT peteragoston prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT klitonjorgo prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT laszlogesztesi prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT gyongyifarkas prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT gaborszekely prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT zoltantakacsinagy prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT csabapolgar prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT gezasafrany prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT zsoltjuranyi prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations AT katalinlumniczky prostatecancersurvivorspresentlongtermresidualsystemicimmunealterations |